opportunistic infections. All will die unless treated by bone marrow transplantation (BMT). For those diagnosed at birth, the prognosis following BMT is excellent. Infants in poor physical condition, particularly from infective lung or liver damage fare much worse, with survival after BMT reduced from 70% to 30%. 1 Children with other severe T and B cell immunodeficiencies are also susceptible to persistent and opportunistic infections which often prove fatal within two decades.
In SCID, the immunodeficiency is more profound and long-lasting than in other immunocompromised patients, such as those receiving cytotoxic chemotherapy. Defective T cell-mediated immunity means that these children cannot eliminate viral infections. Many suffer chronic respiratory viral infection, particularly with paramyxoviruses, leading to significant respiratory compromise. Myeloablative and immunosuppressive conditioning is necessary to ensure donor marrow engraftment following which there is a delay of several weeks until functional T cell immunity develops. Graft-versus-host disease (GVHD) may prolong the period of T cell immunodeficiency by disrupting immune reconstitution. This allows ongoing viral replication as well as causing inflammatory lung damage, so contributing to the risk of developing severe pneumonitis following BMT with a mortality rate of 70% (Ͼ95% if ventilation is required 2 ). Pneumonitis often manifests as a sudden and severe respiratory deterioration either at the time of initial engraftment, or the later emergence of mature T cells, suggesting a role for alloreactive donor cell responses in pathogenesis of this condition. Some children survive, eliminating their viruses following successful T cell engraftment.
To describe the incidence of respiratory viral infections, their range of clinical manifestations and effects on outcome, a series of 73 consecutive children transplanted for SCID and other severe primary immunodeficiencies was studied.
Methods and patients
Case records of 73 infants and children with primary immunodeficiency disorders, diagnosed according to WHO criteria 3 were reviewed. Five children with severe infantile osteopetrosis (which, although not a primary immunodeficiency disorder, does involve defective macrophage function) were included.
All patients received strict reverse barrier nursing under laminar flow isolation from admission until discharge or death. Weekly virological surveillance was performed by the collection of nose and throat swabs, nasopharyngeal aspirate (NPA), urine and stool specimens as well as bronchoalveolar lavage (BAL) on admission, repeated when clinically indicated during periods of respiratory illness. NPA and BAL specimens underwent indirect immunofluorescent antibody testing (IFAT) for respiratory syncytial virus (RSV), parainfluenza viruses (PIV) types 1-4, influenza A and B, adenovirus, measles, herpes simplex (HSV) and cytomegalovirus (CMV). 4 Specimens were routinely innoculated into tissue culture for these viruses and for rhinovirus isolation. Routine CMV surveillance was performed weekly by additional culture of urine and NPA, with CMV antigenaemia and qualitative PCR introduced from 1993. High-dose aciclovir prophylaxis (500 mg/m 2 i.v. every 8 h in children 1 month to 12 years, or 10 mg/kg i.v. every 8 h in neonates and children over 12 years) was administered to all patients in whom donor, recipient or both were CMV positive. All blood products were CMVnegative, irradiated and leucocyte filtered. Patients with positive blood CMV PCR and/or antigenaemia were treated with either ganciclovir 5 mg/kg i.v. every 12 h for 2 weeks, or foscarnet 180 mg/kg i.v. over 24 h.
T cell depletion (TCD) of bone marrow, whenever indicated, was performed using CAMPATH-1-M and complement. Additional GVHD prophylaxis, when indicated, was provided using cyclosporin A (CsA), achieving trough blood levels of 200-300 ng/ml, and methotrexate (MTX) 10 mg/m 2 on days ϩ1, ϩ3 and ϩ6. Acute GVHD was initially treated with i.v. methylprednisolone 1-5 mg/kg/day, as clinically necessary.
Patients' case notes were reviewed regarding clinical condition, details of BMT and conditioning regimens employed, site and nature of infections, serial full blood count and lymphocyte phenotype measurements (to document evidence of engraftment), respiratory function parameters (respiratory rate, oxygen requirement, pulse oximetry and objective clinical measures of respiratory distressformal lung function testing is virtually impossible in small, critically ill infants) and treatments administered.
All patients also received high-dose intravenous immunoglobulin (IVIg), 0.4-1.4 g/kg/week, (Sandoglobulin, Novartis, Pharmaceuticals, Camberley, UK) as passive immunotherapy for the hypogammaglobulinaemia that accompanies most primary immunodeficiencies. All patients with paramyxovirus infections received aerosolised ribavirin (6 g/day over 18 h, or 2 g over 2 h every 8 h) from diagnosis, either until clearance of virus, or complete resolution of respiratory symptoms post BMT. Intravenous ribavirin, if used, was administered at 10 mg/kg every 8 h. Patients with pneumonitis received nebulised immunoglobulin (50 mg/kg every 12 h) and corticosteroid (budesonide) 2 mg every 12 h to 3 h depending on severity of pneumonitis. Inhaled treatment regimens were based upon data from animal models of viral pneumonitis 5 and human studies 6 suggesting this may ameliorate infection.
Results
Twenty-two of 73 children (30%) had respiratory viral infections before, or at the time of transplantation (see Table 1 ). Only one (patient T) acquired respiratory viral infection after admission to a laminar flow cubicle. Seven of these (patients C, D, F, K, L, R, T) died of respiratory viral pneumonitis (32%). Two of the six patients who died of other causes (patients H and S) also had significant respiratory viral infection. Virus was found in NPA in all patients. No patients had virus detected on BAL that was not also detected in NPA. Thirteen patients had multiple viral infections at presentation (including CMV, HSV, adenoviruses, rotavirus, astrovirus and enteroviruses). Paramyxoviruses (RSV and PIV 1-4) were found in 11 of 22 (50%) patients. In 10, viruses were detected at admission with one patient contracting PIV-3 nosocomially during transplantation. Three (27.3%) had RSV, five (45.5%) had PIV-3 and one patient each had PIV-1, PIV-2 and PIV-4. In patients M and R, rhinovirus was also detected. All patients presenting with PIV LRTI were oxygen dependent, with signs and symptoms of severe viral pneumonitis, and virus isolated from both NPA and BAL. All these patients developed worsening of pneumonitis coincident with neutrophil engraftment. Five patients (45.5%) successfully engrafted, cleared their viruses and survived. None of these five patients were ventilated following BMT. Six patients (54.5%) died of severe pneumonitis post BMT, three of whom were ventilated. All patients with paramyxovirus infections were treated with combination aerosol ribavirin and IVIg. In no patient was this associated with an apparent decrease in apparent viral load (measured semiquantitatively by assessing the proportions of IFAT-positive cells in serial NPA specimens 7 ) nor was there a substantial improvement in respiratory symptomatology. The three patients with RSV received high-titre RSV-specific IVIg. Again, no significant improvements in symptoms were seen. Five patients (Q, R, T, U and V) additionally received nebulised immunoglobulin and corticosteroid (budesonide). Three of these five (60%) thus treated survived, compared with two of six (33.3%) patients not receiving nebulised treatment. Nebulised treatment was tolerated well, with no short-or medium-term side-effects detected in survivors to date.
Adenoviruses were found in three patients. Adenovirus type 2 was detected in NPA in one patient with LRTI symptoms (patient A). She subsequently developed disseminated adenovirus infection, including viraemia, and died of candida septicaemia post BMT. Adenovirus type-1, initially isolated from gut in the second patient (patient S), subsequently disseminated to most organs including lung. He died of acute GVHD and disseminated adenoviral infection, despite treatment with intravenous ribavirin. The third patient had asymptomatic adenovirus upper respiratory tract infection (URTI) and eliminated his virus uneventfully following successful BMT.
Rhinoviruses were detected in 11 patients, in nine of whom virus was only detected in NPA specimens. Seven of 11 patients had mild URTI symptoms only at presentation. Four of these seven patients had no significant respiratory problems and cleared their rhinovirus infections on successful engraftment. Three of the seven patients with URTI symptoms had additional viral infections (patient N with CMV, patient L with CMV, HSV and influenza B, and patient S with disseminated adenovirus type 1). The Influenza B, rhinovirus and CMV were isolated from NPA in patient L, who was asymptomatic at admission. He later died from CMV pneumonitis. Although CMV alone was found in lung tissue at post-mortem examination, influenza B and rhinovirus may have contributed to his respiratory symptoms.
Nine of 73 (12.3%) patients had CMV infection of whom five of nine (55.6%) died of CMV disease (three of five from CMV pneumonitis and two of five from disseminated CMV disease). Overall mortality from CMV disease in this series was 6.8%.
Discussion
Children with undiagnosed immunodeficiencies are at risk of community acquired respiratory viral infection, the longer they spend in the community the more likely they are to acquire respiratory viral infection; the diagnosis of immunodeficiency may not be made until such infection leads to hospitalisation. Unfortunately, these infections greatly reduce the chances of successful treatment.
1 Thorough and comprehensive virological surveillance revealed the high incidence of respiratory viral infection in these patients (30%), with multiple viral infections not being uncommon. Virological diagnosis outside specialist centres is often limited; many hospital microbiology departments only provide for rapid immunofluorescent diagnosis of RSV. These children, however, not only present throughout the year, but may have other viral infections such as PIV-2 or 4. The diagnosis may not be considered, or may be missed because samples are not sent to a specialist virology laboratory. Nasopharyngeal aspirate examination revealed the infecting virus in all our cases, illustrating the importance of such specimens. Although relatively easy to obtain, particularly in infants, correct sampling by experienced children's nurses and physiotherapists is essential if speci-mens are to contain sufficient cellular material for reliable IFAT.
In LRTI, virus was consistently recovered from both NPA and BAL specimens whereas in Pneumocystis carinii infection the organism is rarely isolated from NPA, but almost always from BAL. 8 Paramyxovirus infection was generally established at presentation, invariably caused severe viral pneumonitis in SCID, which abruptly worsened at the time of engraftment, and carried a poor prognosis. Paramyxoviruses found in the URT were always present in the LRT as well, so LRTI must be presumed if the initial NPA is positive, even if other organisms, such as Pneumocystis carinii are also detected. This is important, as prompt, aggressive respiratory treatment is vital to prevent progressive, severe respiratory disease, which makes BMT more risky. Antiviral and anti-inflammatory therapies for pneumonitis, appeared to benefit these patients, but viral clearance only occurred when functionally mature T cells appeared. This could take several months, particularly in children who have received T cell-depleted mismatched transplants and so, treatment should therefore continue until this is achieved. By contrast, rhinoviruses caused asymptomatic infection or coryzal symptoms only and were only isolated from URT secretions. Even in the absence of T cell immunity, rhinoviruses appeared incapable of infecting the LRT, presumably due to its intolerance of the higher LRT temperature; only the URT temperature (ෂ33°C) being suitable for viral growth. Rhinoviruses may have been facultative pathogens in patients H and O where other lung pathology was present, and rhinovirus was isolated from BAL specimens. There have been other reports of rhinoviral pneumonia in patients with respiratory or cardiovascular disease, or immunocompromise, due to malignancy. 9 Adenoviruses are ubiquitous pathogens and many serotypes cause disease in several sites, including the lung. 10 Disseminated multiorgan disease is more common in severely immunosuppressed patients and carries a poor prognosis. Although there is no specific treatment, intravenous ribavirin has been used in both respiratory and disseminated disease, with variable results; 11, 12 no apparent drug benefit was seen in our patient (S) with disseminated adenovirus and pneumonia.
Treatment of respiratory viral infection is difficult since functional T cell immunity is required to eliminate virus. This is not possible in these children until immunity is attained following successful BMT. Management therefore is aimed at limiting viral replication, treating virally induced inflammation, treating concurrent infection and optimising respiratory function. Viral neutralisation and inactivation may be attempted using immunoglobulin and antiviral drugs, particularly in combination. Immunity to RSV is associated with the presence of neutralising antibody, evidenced by the passive protection afforded to atrisk infants by anti-RSV hyperimmune globulin (Respigam, Medimmune, Gaithersburg, MD, USA). 13 Infants with SCID do not make antibody and the replacement intravenous immunoglobulin (IVIg) given provides passive immunity against most respiratory viruses, but alone did not clear virus in any patient. We also saw no clinical advantage of RSV-specific IVIg over the standard preparation in those patients thus treated despite a theoretical Bone Marrow Transplantation treatment advantage.
14 Antiviral drugs alone cannot eliminate virus. Ribavirin, a guanosine analogue, has in vitro activity against many viruses, including common respiratory viruses. Although no controlled trials of its use in immunocompromised patients have been performed, anecdote suggests it helps in RSV and PIV infections when given early in conjunction with intravenous immunoglobulin (IVIg). [15] [16] [17] [18] In our series no patient cleared RSV or PIV prior to T cell engraftment, even when intravenous ribavirin was added, although progressive viral infection might have been prevented. Ribavirin was well tolerated, apart from acute, reversible thrombocytopoenia in one patient treated with i.v. ribavirin.
Viral replication occurs predominantly in the respiratory epithelium. While secretory IgA provides effective mucosal immunity in the upper respiratory tract, IgG, derived from the circulation, predominates in the lower respiratory tract. Although high circulating levels can be achieved with IVIg, antibody penetrates poorly into respiratory secretions. 14 Increasing local levels with topically administered antibody could substantially increase viral neutralisation and ameliorate disease. Animal models of viral pneumonitis show convincing viral elimination using either topically applied immunoglobulin, or aerosolised immunoglobulin. [19] [20] [21] Experience of aerosolised immunoglobulin in humans, is limited to one study of normal infants with RSV bronchiolitis 6 which showed it to be well tolerated. Corticosteroids have not been shown to help in viral bronchiolitis but have been of considerable benefit in cotton rats with PIV-3 pneumonitis. When treated with topical antibody, they showed enhanced viral clearance, but still developed pneumonitis. Conversely, rats treated with topical steroids, failed to clear virus, but did not develop pneumonitis. Combination of both treatments resulted in reductions both in viral load and in pneumonitis. 5 We used nebulised immunoglobulin with nebulised corticosteroids in three patients with PIV pneumonitis, and one with RSV pneumonitis. One patient with RSV infection received both nebulised corticosteroid and nebulised anti-RSV hyperimmune globulin. This combination therapy, in addition to IVIg and ribavirin appeared to benefit these five patients when they were compared with six historical patients who received no such treatment. 22 As viral clearance was not achieved using this approach, neutralisation of free virus and local control of inflammation presumably was clinically beneficial both prior to BMT and once engrafted lymphocytes began to eliminate virus from the lungs, causing bystander inflammation in the process.
The profound and prolonged lack of T cell immunity in severe primary immunodeficiencies allows respiratory viruses, especially paramyxoviruses and adenoviruses to become important causes of mortality and morbidity in these children undergoing BMT. Treatment is difficult as no agent clears virus until functional T cell activity is achieved. Multiple viral infections, not only respiratory viruses, but also viruses in other organ systems, can cause additional debility and morbidity, significantly complicating management and outcome. Antiviral agents may limit viral replication and tissue damage, and with nebulised immunoglobulin and corticosteroid anti-inflammatory treatments, improve symptoms both before and after BMT possibly conferring a survival advantage to these children. This approach warrants further study and could be considered in other patients where there is altered immunity, viral infection and severe inflammation, such as in lung transplant patients, and those with chronic lung diseases.
